婴儿4CMenB疫苗减少接种程序及儿童补种程序的免疫原性与安全性:一项随机开放标签3b期试验结果
本开放标签多中心3b期试验评估婴儿按减少程序接种4CMenB疫苗及儿童补种的免疫原性与安全性。754名婴儿随机接受2+1或3+1程序,404名2-10岁儿童接受2剂补种。减少程序在fHbp、NadA、PorA上达到预设充分性标准,各程序免疫原性良好且安全性相似,45例严重不良事件中3例与接种相关。
要点
- 婴儿2+1程序(3½-5-11月或6-8-11月龄)在fHbp、NadA、PorA上达到预设免疫充分性标准。
- 初免后98-100%婴儿对fHbp、NadA、PorA产生hSBA滴度≥4,NHBA为48-77%。
- 儿童2剂补种后95-99%对4CMenB组分产生hSBA滴度≥4,各组安全性相似。
核心结论
- 婴儿减少接种程序及儿童补种程序具有免疫原性和安全性,有潜力扩大4CMenB疫苗覆盖范围。
研究设计与样本
- 开放标签、多中心、3b期随机试验(NCT01339923),婴儿按1:1:1随机接受2+1程序(3½-5-11月龄或6-8-11月龄)或3+1程序(2½-3½-5-11月龄),2-10岁儿童接受2剂补种(间隔2个月)。
主要发现
- 初免后98-100%婴儿对fHbp、NadA、PorA产生hSBA滴度≥4,NHBA为48-77%。
- 接受2+1程序的婴儿在2剂后fHbp、NadA、PorA达到预设充分性标准(97.5%CI下限≥70%)。
- 儿童2剂补种后95-99%对4CMenB组分产生hSBA滴度≥4。
- 共报告45例严重不良事件,其中3例与接种相关。
关键数值与推荐
- 2+1程序免疫充分性标准:第2剂后1个月hSBA滴度≥4的婴儿百分比,其97.5%置信区间下限≥70%(针对fHbp、NadA、PorA)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the immunogenicity and safety of a licensed meningococcal serogroup B vaccine (4CMenB) administered alone according to reduced schedules in infants or catch-up series in children. METHODS: In this open-label, multicentre, phase 3b study (NCT01339923), infants randomised 1:1:1 received 4CMenB: 2+1 doses at 3½-5-11months or 6-8-11months of age, 3+1 doses at ages 2½-3½-5-11months. Children aged 2-10years received 2 catch-up doses administered 2months apart. Immune responses were measured by hSBA assays against 4 strains specific for vaccine components fHbp, NadA, PorA and NHBA. Sufficiency of immune responses was defined in groups with 2+1 doses schedules as a lower limit ≥70% for the 97.5% confidence interval of the percentage of infants with hSBA titres ≥4, 1month post-dose 2 for fHbp, NadA, PorA. Adverse events were collected for 7days post-vaccination; serious adverse events (SAEs) throughout the study. RESULTS: 754 infants and 404 children were enrolled. Post-primary vaccination, 98-100% of infants across all groups developed hSBA titres ≥4 for fHbp, NadA, PorA, and 48-77% for NHBA. Sufficiency of immune responses in infants receiving 2+1 schedules was demonstrated for fHbp, NadA, PorA after 2 doses of 4CMenB, as pre-specified criteria were met. Following receipt of 2 catch-up doses, 95-99% of children developed hSBA titres ≥4 for 4CMenB components. Similar safety profiles were observed across groups. A total of 45 SAEs were reported, 3 of which were related to vaccination. CONCLUSION: Reduced infant schedules and catch-up series in children were immunogenic and safe, having the potential to widen 4CMenB vaccine coverage. FUNDING: GlaxoSmithKline Biologicals SA.
引用
- Martinón-Torres F, Safadi MAP, Martinez AC, et al. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial. Vaccine. 2017. PMID: 28533054. doi:10.1016/j.vaccine.2017.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。